ArticleDiscover oncology2025
Genetic determinants of head and neck cancer: exploring causality among immune cells and plasma metabolites through two-sample Mendelian randomization and mediation analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancer represents a major health challenge worldwide, characterized by frequent late-stage diagnoses that adversely affect treatment success. The immune system's cellular components significantly influence the initiation, advancement, and outcome of head and neck malignancies.
methodsOur investigation employed Mendelian randomization techniques to analyze genome-wide association data encompassing 731 immune cell phenotypes, 1400 plasma metabolites, and 2281 head and neck cancer patients. We utilized mediation analysis to assess how plasma metabolites might serve as intermediaries between immune cells and head and neck cancer development. We evaluated heterogeneity using IVW and MR-Egger approaches, examined pleiotropy through MR-Egger intercepts, and conducted sensitivity testing via the leave-one-out methodology.
resultsOur analysis revealed potential causal connections linking three immune cell phenotypes and twelve plasma metabolites to head and neck cancer. Through mediation Mendelian randomization, we identified that 3-hydroxypyridine glucuronide concentrations function as a mediator between CD3 on CD39 + secreting Treg cells and head and neck cancer. The measured mediating effect was - 0.011, 95%CI (-0.02, -0.002), representing a mediating proportion of 9.27%. Additionally, we also found that CD3 on CD39 + secreting Treg mediated Cortolone glucuronide (1) levels and CD80 on granulocyte mediated 3-amino-2-piperidone levels exhibit the masking effect on head and neck cancer.
conclusionsThese discoveries provide fresh perspectives on the intricate interactions occurring within the tumor microenvironment and may highlight potential targets for reducing head and neck cancer risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.